{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:30:50Z","timestamp":1767994250465,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.tracli.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T02:28:47Z","timestamp":1626920927000},"page":"60-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India"],"prefix":"10.1016","volume":"29","author":[{"given":"R.","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Amoncar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Palyekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.P.","family":"Adsul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2021.07.004_bib0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2021.07.004_bib0130","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"10.1016\/j.tracli.2021.07.004_bib0135","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10096-020-03874-z","article-title":"The epidemiology and clinical information about COVID-19","volume":"39","author":"Ge","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.tracli.2021.07.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85247-w","article-title":"Point-of-care serological assays for SARS-CoV-2 in a UK hospital population: potential for enhanced case finding","volume":"11","author":"Pallett","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.tracli.2021.07.004_bib0145","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.tracli.2021.07.004_bib0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2021.07.004_bib0155","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect Dis"},{"key":"10.1016\/j.tracli.2021.07.004_bib0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.tracli.2021.07.004_bib0165","unstructured":"Central Drugs Standard Control Notice. https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NjA0Mw= Accessed on 07 March 2021."},{"key":"10.1016\/j.tracli.2021.07.004_bib0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/ijmr.IJMR_3290_20","article-title":"Prevalence of SARS-CoV-2 infection in India: Findings from the national sero survey, May\u2013June 2020","volume":"152","author":"Murhekar","year":"2020","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.tracli.2021.07.004_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.11606\/s1518-8787.2020054002643","article-title":"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil","volume":"54","author":"Amorim Filho","year":"2020","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.tracli.2021.07.004_bib0180","first-page":"14","article-title":"Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a Metropolitan City from India","volume":"68","author":"Goenka","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.tracli.2021.07.004_bib0185","series-title":"CDSCO gov in","author":"Acts & Rules","year":"2020"},{"key":"10.1016\/j.tracli.2021.07.004_bib0190","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.tracli.2021.07.004_bib0195","doi-asserted-by":"crossref","first-page":"e02005","DOI":"10.1128\/JCM.02005-20","article-title":"Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.tracli.2021.07.004_bib0200","unstructured":"Ray Y, Paul S, Bandopadhyay P, D\u2019Rozario R, Sarif J, Lahiri A, et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]. (2020). 10.1101\/2020.11.25.20237883 [CrossRef] [Google Scholar]."},{"key":"10.1016\/j.tracli.2021.07.004_bib0205","doi-asserted-by":"crossref","first-page":"102923","DOI":"10.1016\/j.transci.2020.102923","article-title":"Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan","volume":"59","author":"Younas","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2021.07.004_bib0210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/cid\/ciaa1150","article-title":"Relationship between the ABO blood group and the COVID-19 susceptibility","volume":"73","author":"Zhao","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2021.07.004_bib0215","doi-asserted-by":"crossref","unstructured":"Siddiqui S, Naushin S, Pradhan S, Misra A, Tyagi A, Loomba M, et al. SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital setting. medRxiv preprint. doi: 10.1101\/2020.09.02.20186486","DOI":"10.1101\/2020.09.02.20186486"},{"issue":"3","key":"10.1016\/j.tracli.2021.07.004_bib0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.9734\/ibrr\/2021\/v12i330151","article-title":"Performance evaluation: four chemiluminescent SARS-Cov-2 immunoassays and rapid-card test in mild disease and seroprevalence of SARS CoV-2 in frontline healthcare workers","volume":"12","author":"Setia","year":"2021","journal-title":"Int Blood Res Rev"},{"key":"10.1016\/j.tracli.2021.07.004_bib0225","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1128\/MMBR.00024-15","article-title":"Deconstructing the antiviral neutralizing-antibody response: implications for vaccine development and immunity","volume":"80","author":"VanBlargan","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.tracli.2021.07.004_bib0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0973-6247.76001","article-title":"Donor deferral due to anemia: a tertiary care center-based study","volume":"5","author":"Bahadur","year":"2011","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.tracli.2021.07.004_bib0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/joah.joah_6_17","article-title":"Analysis of plateletpheresis donor deferral rate, characteristics, and its preventability","volume":"8","author":"Dogu","year":"2017","journal-title":"J Appl Hematol"},{"key":"10.1016\/j.tracli.2021.07.004_bib0240","first-page":"1","article-title":"COVID-19 reinfection: myth or truth?","author":"Roy","year":"2020","journal-title":"SN Compr Clin Med"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:25Z","timestamp":1761129565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782021000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1246782021000938"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2021.07.004","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}